Myelodysplastic Syndrome (MDS) Treatment Market will grow at 8.9% CAGR, to be valued at US$ 4,994.7 Million by 2027
Global Myelodysplastic Syndrome Treatment Market
With growing public awareness about myelodysplastic syndrome (MDS) and availability of new treatment options for MDS, the global myelodysplastic syndrome treatment market is poised to witness tremendous growth over the forecast period.
Early diagnosis of MDS is essential, as it significantly increases the quality of life of patients, reducing the chances of recurrent blood transfusion and in more severe cases, the evolution of the disease into leukemia. Government organizations and drug manufacturing companies across the world are majorly focusing on spreading awareness about the disease by conducting funding and conducting awareness programs. For instance, in October 2018, Grupo Biotoscana, a Latin American biopharmaceuticals company, conducted a campaign to honor the World Myelodysplastic Syndrome Awareness Day, celebrated on October 25 each year. GBT Grupo Biotoscana launched a campaign to raise awareness and educate about disease throughout the month.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/775
The global myelodysplastic syndrome treatment market was pegged at US$ 2,324.8 million in 2018, and is expected to exhibit a staggering 8.9% CAGR during the forecast period (2019-2027).
Increasing regulatory approvals for MDS therapeutics is a driving factor for the global market development
Increasing regulatory approvals is expected to drive growth of the global myelodysplastic syndrome treatment market over the forecast period. For instance, in November 2018, Lupin received the U.S. FDA approval for its Decitabine for Injection, 50 mg/vial, a single-dose vial, as well as a generic version of Otsuka Pharmaceutical’s Dacogen for Injection, 50 mg/vial, a single-dose vial.
Increasing approvals of Azacitidine in key regions around the world is expected to drive the growth of the Azacitidine segment of the global myelodysplastic syndrome treatment market in the following years. For instance, in February 2018, BeiGene, Ltd. announced the commercial availability of VIDAZ (azacitidine for injection) in China. VIDAZA is approved in China for patients with intermediate-2 / high-risk myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) with 20-30% bone marrow blasts, and chronic myelomonocytic leukemia (CMML). For the record, the drug is extensively marketed in China by BeiGene, under an exclusive license from Celgene Corporation.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/775
Increased complexity of MDS disease and its true diagnosis in patients act as a major hurdle in effective MDS treatment, which is expected to hamper the global market growth
MDS is said to represent several different conditions, as it is not just a single disease, but a group of several clinical characteristics. According to the data published in the Hematology journal of the American Society of Hematology Education Program in December 2017, the type and severity of hematopoietic dysfunction in MDS are highly variable, while the kinetics of disease progression are not quite predictable.
Moreover, genetic characteristics of MDS are powerfully associated with clinical phenotype. An enhanced understanding of the regulatory logic of MDS genetics may stimulate refined and biologically based diagnostic and monitoring schema that may be integrated into clinical practice.
Global Myelodysplastic Syndrome Treatment Market- Regional Analysis
On the basis of geography, the global myelodysplastic syndrome treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is estimated to dominate the global market throughout the forecast timeline, owing to the presence of major players and non-profit organizations in the region that are focused on launching new programs and awareness campaigns to educate people about various MDS treatments. According to the report, the U.S. market would expand significantly over the forecast period, owing to rising awareness among the U.S. population about MDS. Based on the American Cancer Society’s 2018 data, the number of people diagnosed with myelodysplastic syndrome (MDS) in the U.S. each year varies between 10,000 and 30,000, approximately 55,000 new cases are diagnosed each year.
Europe is projected to witness fast-paced growth over the forecast period, owing to rising government initiatives for the diagnosis and treatment of the disease. For instance, in 2014, the European LeukemiaNet WP8 promoted a program aimed at developing and continuously updating evidence- and consensus-based guidelines to provide clinical practice recommendations for standardized diagnostic and prognostic procedures, as well as for an appropriate choice of therapeutic interventions in adult patients suffering from primary MDS.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/increase-in-diagnosis-rate-is-expected-to-surge-the-myelodysplastic-syndrome-treatment-market-to-us-57-bn-2025-343
Global Myelodysplastic Syndrome Treatment Market – Competitive Scenario
The well-known players operating in the global myelodysplastic syndrome treatment market include Celgene Corporation, Otsuka Pharmaceutical Co., Ltd. Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma, Inc., Aprea Therapeutics, FibroGen Inc., Onconova Therapeutics Inc., and Geron.
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Pipeline Analysis
- Mergers and Acquisitions
- Regulatory Scenario
- Reimbursement Scenario
- PEST Analysis
- Market Dynamics
- Global Myelodysplastic Syndrome (MDS) Treatment Market, By Drug, 2016 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Lenalidomide
- Decitabine
- Azacitidine
- Phase 3 Drugs
- Introduction
- Global Myelodysplastic Syndrome (MDS) Treatment Market, By Route of Administration, 2016 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Injection
- Oral
- Introduction
- Global Myelodysplastic Syndrome (MDS) Treatment Market, By Distribution Channel, 2016 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Introduction
- Global Myelodysplastic Syndrome (MDS) Treatment Market, By Region, 2016 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, By Region, 2017 – 2027
- Regional Trends
- North America
- Market Size and Forecast, By Drug, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Drug, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Drug, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Drug, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
- North Africa
- Central Africa
- South Africa
- Middle East
- Market Size and Forecast, By Drug, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Celgene Corporation
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Otsuka Pharmaceutical Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Limited
- Dr. Reddy’s Laboratories Ltd.
- Mylan NV
- Cipla Limited
- Acceleron Pharma, Inc.
- Aprea Therapeutics
- FibroGen Inc.
- Onconova Therapeutics Inc.
- Geron
- Celgene Corporation
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- CDN Newswire
